Conference call to discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF will be held on November 13 at 4:30 pm. Webcast Link
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX:
- Tenax Therapeutics Reports Increased R&D Expenses Amid Clinical Trials
- Tenax Therapeutics reports Q3 EPS (40c), consensus ($1.12)
- TENX Earnings this Week: How Will it Perform?
- Tenax Therapeutics Advances Phase 3 Study on Levosimendan for PH-HFpEF
- Tenax Therapeutics management to meet with Piper Sandler